NasdaqCM:DVAX

Stock Analysis Report

Executive Summary

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation.

Snowflake

Fundamentals

High growth potential and slightly overvalued.

Risks

  • Dynavax Technologies has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Dynavax Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

18.0%

NasdaqCM:DVAX

-0.2%

US Biotechs

-1.0%

US Market


1 Year Return

-68.3%

NasdaqCM:DVAX

-8.1%

US Biotechs

-0.4%

US Market

DVAX underperformed the Biotechs industry which returned -10% over the past year.

DVAX underperformed the Market in United States of America which returned -1.7% over the past year.


Share holder returns

DVAXIndustryMarket
7 Day18.0%-0.2%-1.0%
30 Day5.3%-0.2%-3.3%
90 Day-36.7%2.4%0.4%
1 Year-68.3%-68.3%-7.3%-8.1%1.8%-0.4%
3 Year-75.4%-75.4%9.7%5.9%39.4%30.4%
5 Year-72.1%-72.1%7.8%2.8%54.2%37.1%

Price Volatility Vs. Market

How volatile is Dynavax Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Dynavax Technologies undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Dynavax Technologies's share price is below the future cash flow value, and at a moderate discount (> 20%).

Dynavax Technologies's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Dynavax Technologies is loss making, we can't compare its value to the US Biotechs industry average.

Dynavax Technologies is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Dynavax Technologies, we can't assess if its growth is good value.


Price Based on Value of Assets

Dynavax Technologies is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Dynavax Technologies expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

62.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Dynavax Technologies's revenue is expected to grow significantly at over 20% yearly.

Dynavax Technologies's earnings are expected to grow significantly at over 20% yearly.

Dynavax Technologies's revenue growth is expected to exceed the United States of America market average.

Dynavax Technologies's earnings growth is expected to exceed the United States of America market average.

Dynavax Technologies's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Dynavax Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Dynavax Technologies performed over the past 5 years?

-11.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Dynavax Technologies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Dynavax Technologies's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Dynavax Technologies's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Dynavax Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Dynavax Technologies has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Dynavax Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Dynavax Technologies's financial position?


Financial Position Analysis

Dynavax Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Dynavax Technologies's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Dynavax Technologies's level of debt (1668.3%) compared to net worth is high (greater than 40%).

Unable to establish if Dynavax Technologies's debt level has increased without past 5-year debt data.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.1x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Dynavax Technologies has less than a year of cash runway based on current free cash flow.

Dynavax Technologies has less than a year of cash runway if free cash flow continues to grow at historical rates of 14.9% each year.


Next Steps

Dividend

What is Dynavax Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Dynavax Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Dynavax Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Dynavax Technologies has not reported any payouts.

Unable to verify if Dynavax Technologies's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Dynavax Technologies has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Dynavax Technologies's salary, the management and board of directors tenure and is there insider trading?

4.6yrs

Average management tenure


CEO

Dynavax Technologies has no CEO, or we have no data on them.


Management Age and Tenure

4.6yrs

Average Tenure

66yo

Average Age

The tenure for the Dynavax Technologies management team is about average.


Board Age and Tenure

7.6yrs

Average Tenure

72yo

Average Age

The tenure for the Dynavax Technologies board of directors is about average.


Insider Trading

More shares have been bought than sold by Dynavax Technologies individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$49,99812 Aug 19
Peggy Phillips
EntityIndividual
Role
Member of the Board of Directors
Shares16,666
Max PriceUS$3.00
BuyUS$50,00112 Aug 19
Francis Cano
EntityIndividual
Role
Member of the Board of Directors
Shares16,667
Max PriceUS$3.00
BuyUS$50,00112 Aug 19
David Novack
EntityIndividual
Role
Interim Co-President & Co-Principal Executive Officer
Shares16,667
Max PriceUS$3.00
SellUS$282,07704 Jun 19
Michael Ostrach
EntityIndividual
Role
CFO, Chief Business Officer & Senior VP
Shares31,694
Max PriceUS$8.90
SellUS$187,50802 Mar 19
David Johnson
EntityIndividual
Role
VP & Chief Accounting Officer
Shares20,765
Max PriceUS$9.03
SellUS$570,71402 Mar 19
Robert Coffman
EntityIndividual
Role
Chief Scientific Officer & Senior VP
Shares63,202
Max PriceUS$9.03
SellUS$20,94208 Dec 18
Francis Cano
EntityIndividual
Role
Member of the Board of Directors
Shares2,000
Max PriceUS$10.47

Ownership Breakdown


Management Team

  • Cecilia Vitug

    Vice President of Human Resources

    • Tenure: 12.8yrs
  • Michael Ostrach (67yo)

    CFO, Chief Business Officer & Senior VP

    • Tenure: 4.4yrs
    • Compensation: $3.56m
  • Dennis Carson (72yo)

    Co-Founder

    • Compensation: $196.77k
  • Rob Janssen (65yo)

    Chief Medical Officer & Senior VP of Clinical Development

    • Tenure: 6.1yrs
    • Compensation: $1.74m
  • Ryan Spencer

    Co-President & Co-Principal Executive Officer

    • Tenure: 0.3yrs
  • Heather Rowe

    Vice President of Investor Relations & Corporate Communications

    • Tenure: 0.6yrs
  • David Novack (57yo)

    Interim Co-President & Co-Principal Executive Officer

    • Tenure: 0.3yrs
    • Compensation: $1.70m
  • Bob Coffman (72yo)

    Chief Scientific Officer & Senior VP

    • Tenure: 18.7yrs
    • Compensation: $3.63m
  • Steven Gersten

    Chief Ethics & Compliance Officer

    • Tenure: 4.6yrs
  • David Johnson (65yo)

    VP & Chief Accounting Officer

    • Tenure: 5.5yrs

Board Members

  • Francis Cano (72yo)

    Director

    • Tenure: 9.8yrs
    • Compensation: $208.77k
  • Dan Kisner (72yo)

    Director

    • Tenure: 9.1yrs
    • Compensation: $213.77k
  • Dennis Carson (72yo)

    Co-Founder

    • Tenure: 21.7yrs
    • Compensation: $196.77k
  • Laura Q. Chow

    Member of Scientific Advisory Board

    • Tenure: 1.2yrs
  • Nat Ricciardi (70yo)

    Director

    • Tenure: 6.2yrs
    • Compensation: $201.77k
  • Miriam Merad

    Member of Scientific Advisory Board

    • Tenure: 1.2yrs
  • Stanley Plotkin (86yo)

    Member of Scientific Advisory Board

    • Tenure: 1.2yrs
    • Compensation: $20.00k
  • Arnie Oronsky (80yo)

    Chairman

    • Tenure: 13.5yrs
    • Compensation: $231.77k
  • Peggy Phillips (65yo)

    Director

    • Tenure: 13.0yrs
    • Compensation: $221.77k
  • Laura Brege (61yo)

    Director

    • Tenure: 4.5yrs
    • Compensation: $216.77k

Company Information

Dynavax Technologies Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Dynavax Technologies Corporation
  • Ticker: DVAX
  • Exchange: NasdaqCM
  • Founded: 1996
  • Industry: biotechnology
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$333.882m
  • Shares outstanding: 83.68m
  • Website: Click here

Number of Employees


Location

  • Dynavax Technologies Corporation
  • 2929 Seventh Street
  • Suite 100
  • Berkeley
  • California
  • 94710
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DVAXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 2004
DYF1DB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2004
0IDALSE (London Stock Exchange)YesCommon StockGBUSDFeb 2004

Biography

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company m ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/16 23:54
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.